Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

Published:2020-03-15 Issue:3 Volume:12 Page:301-310
ISSN:1948-5204
Container-title:World Journal of Gastrointestinal Oncology
language:
Short-container-title:WJGO

Author:

Ricci Vincenzo,Granetto Cristina,Falletta Antonella,Paccagnella Matteo,Abbona Andrea,Fea Elena,Fabozzi Teresa,Nigro Cristiana Lo,Merlano Marco Carlo

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,Oncology

Reference26 articles.

1. Cancer statistics, 2019

2. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

3. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

4. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment;Cancers;2023-11-02

2. Serum Cytokine and miRNA Levels Are Differently Expressed in Right- and Left-Sided Colon Cancer;Journal of Clinical Medicine;2023-09-15

3. Mendelian randomization investigation of the causal association between circulating cytokines and colorectal cancer;2023-07-10

4. A joint profile of cytokines and immune cell populations may identify HNSCC patients who benefit from nivolumab treatment. The Gruppo Oncologico Nord-Ovest (GONO) study Nivactor T-2;2023-05-23

5. Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice;European Journal of Medical Research;2023-04-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3